CytoSorbents Corporation 2025 Annual Report – Investor Analysis
CytoSorbents Corporation: 2025 Annual Report Highlights & Investor Analysis
Key Points from the Annual Report
- Fiscal Year End: December 31, 2025
- Exchange & Trading Symbol: Nasdaq Capital Market (Nasdaq Capital Market); Symbol: CTSO
- Public Float: Approx. \$60.6 million as of June 30, 2025
- Shares Outstanding: Approx. 62.7 million shares as of March 20, 2026
- Company Status: Non-accelerated filer, smaller reporting company, not an emerging growth company
- SEC Compliance: Filed all required reports (Sections 13/15(d)), submitted all Interactive Data Files
- Internal Controls: Management’s assessment of the effectiveness of internal controls over financial reporting has been attested by the company’s auditor
- Error Corrections: The financial statements reflect correction of errors to previously issued statements, but no restatement requiring recovery analysis of executive incentive-based compensation
- Shell Company Status: Not a shell company
- Patent Portfolio: 24 issued US patents, multiple foreign patents, and pending applications. Patent terms expire between 2026 and 2044.
- Products & Trademarks: CytoSorb, CytoSorb XL, ECOS-300CY, BetaSorb, ContrastSorb, DrugSorb, DrugSorb-ATR, HemoDefend-RBC, HemoDefend-BGA, K+ontrol, VetResQ, PuriFi
Potentially Price-Sensitive Information for Shareholders
-
Correction of Errors in Financial Statements:
The annual report confirms that corrections have been made to previously issued financial statements. This is noteworthy, as any material corrections can impact investor confidence and share price, depending on the nature and magnitude of the errors. However, the company states that these corrections did not result in any restatements requiring recovery analysis of incentive-based compensation for executives.
-
Patent Expiry Risk & IP Strength:
The company’s patent portfolio includes 24 US patents, with some expiring as early as 2026. Investors should be aware of the risk of near-term patent expirations potentially impacting the company’s competitive position and revenue streams, especially if key patents expire. Management believes that any near-term expiring patents will not materially affect operations, but this is a risk factor to monitor.
-
Market Value & Liquidity:
CytoSorbents’ public float is \$60.6 million and shares outstanding are 62.7 million. This provides insight into liquidity and potential volatility. Significant changes in float or share count, or in trading volume, can impact share price.
-
Regulatory and Compliance Status:
The company is fully compliant with SEC reporting and Sarbanes-Oxley Act requirements, including auditor attestation of internal controls. This strengthens investor confidence in governance and transparency, potentially supporting share value.
-
Business Segment & Growth:
The company is not a shell company and is classified as a smaller reporting company. This means it may have less regulatory overhead but could face growth and scalability challenges.
-
Documents Incorporated by Reference:
Parts of the definitive proxy statement (to be filed within 120 days) are incorporated by reference, which may include additional information relevant to investors, such as executive compensation, corporate governance, and related party transactions.
Risk Factors & Forward-Looking Statements
The report contains forward-looking statements regarding future operations, strategies, cash flows, and management objectives. These statements are subject to risks and uncertainties, including but not limited to:
- Patent expirations impacting product exclusivity
- Business scalability as a smaller reporting company
- Potential impact from corrections to financial statements
- Regulatory changes or compliance issues
Investors should monitor subsequent filings and proxy statements for updates on these areas.
Trademark Protection:
CytoSorbents has robust trademark and patent protections for its product lines, but use of other parties’ trademarks does not imply endorsement.
Summary for Investors
CytoSorbents Corporation’s 2025 Annual Report reveals strong compliance with SEC regulations, a significant patent portfolio, and ongoing corrections to financial statements. The company’s competitive position is supported by intellectual property but faces risks from patent expirations and prior financial statement errors. Investors should closely monitor future proxy filings and any disclosures regarding patent expirations, operational changes, or financial adjustments, as these could materially affect share value.
Disclaimer: This article is for informational purposes only and is not investment advice. Investors should conduct their own due diligence and consult financial advisors before making investment decisions. The information presented is based on the company’s annual report and may be subject to change. Forward-looking statements are subject to risks and uncertainties and may not reflect actual future performance.
View Cytosorbents Corp Historical chart here
